Member Info for Vulcan998

This RNS is a holding statement only - hopefully more meaningful news after the weekend....

The NAV update is very good though!

Just hope the deal does not go like MXCP which basically screwed the PI's as they backed away from the market leaving the PI holding non listed shares (if they could) for up to 2 years. Most have had to sell.

Some more fiddling around with one of the assets - this time doing something diametrically opposite (small round graphite for anodes) compared to the last test exercise ( large flake graphite)........

I am really losing my patience now.

The BOD are happy getting their salaries, doing science etc. They do not seem to understand commercial reality.

I have now sold my original investment in this share and am lucky enough to be on a free ride - always hate doing this but it seems the sensible approach given the wild fluctuations - I still have quite a lot of skin in the game though

and the good thing about sales to the rail industry is once one operator starts using it and getting benefits some of the others are likely to follow........there is a lot of cross fertilisation of ideas and approaches

What do we think is a realistic sales target? And of course there must be a manufacturing production limit as well

Paris, France and Camberley, UK - 14 February 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that, further to its announcement on 7 February 2020, its subsidiary, Primerdesign Limited, is on schedule to launch a CE-Mark approved nCoV test in the week commencing 17 February 2020. The Primerdesign website has commenced taking orders for the CE-marked test ahead of the planned launch next week.

Very good results - all positive metrics with large increases in profit and turnover.

The only negative metric I can find is the Net Interest Margin but the text explains that this is due to seeking out higher quality loans to fund.......

So the NAV was 117p so if the firm cancels from AIM I would assume we would get this per share (plus/minus any changes since the Final Results).........

I would assume the NAV includes the circa£70M in cash on the balance sheet as well......

there are tests ongoing using 20% hydrogen in house hold boilers as apparently this is the maximum that will work without alterations.

You are right about Hydrogen atom being small and difficult to contain - in a past life I used H2 gas for leak detection in scientific apparatus BUT we also used standard rubber o-rings for sealing......

I have always thought this Clogau project is more of a hobby than an investment.......unfortunately all of their projects seem to be going the same way with little real progress towards making them commercial

I am still invested here BUT am very tired of the depressing share price drop over the last few years with little sign of improvement.......Horse Hill is the only one anywhere near being commercial (and that is because UKOG drive it forward not Alba)

https://www.dailymail.co.uk/sciencetech/article-7936115/Popular-anti-virus-company-revealed-selling-web-history-porn-searches-location-users.html

Bad in terms of people not wanting to use Avast, good in terms of new revenue streams.......think I am going to reduce my holding again

I am not sure how this book build will work at a price lower than the current price. I am not sure many of the larger holders will put shares up for this.......

but now we are moving upwards!

yes excellent results - but only a 2 - 3% increase so far. unfortunately.

Key valuation section from the report by Hannam:

We have assumed an ilmenite price of US$200/t and a WACC of 8%, more conservative than
the PFS inputs of US$232/t and 5%. However, based on the potential size of the Resource, we
have modelled 17 years of production beyond the 9-year PFS Reserve. We have also stripped
US$45m from the capex budget and assume 12% lower unit operating costs in real terms. On
this basis we reach an NPV of US$253m for Dundas, to which we apply a 0.8x multiple. We
then add US$40m for Disko and Kangerluarsuk (vs ~US$100m historical spend), and US$20m
for JAY’s Finnish assets. Adjusting for working capital and G&A, we derive a total Dec’20E
SOTP of ~US$254m or 20p/sh, implying 126% upside to the share price. Furthermore, we note
for every US$10/t delta in ilmenite we would see a ~US$40m change (~16%) in our Dundas
NPV, equivalent to a ~2.6p change in SOTP; marking-to-market for current ilmenite prices of
~US$230/t, this would imply ~40% further upside to our PT.

Reading the RNS pre open this morning I was rather negative about it - things just seem to be drifting on with little apparent drive to actually generate money from any of the assets just keep testing! The fact that 3 assets are now effectively paused may mean they could be negotiating with other parties to develop them and this may generate some cash short term so an RNS update on this would be good. Also we still await the HH2Z news.

BUT on a positive note First Equity have retained their buy status on Alba this morning (only Broker currently covering) - they did have a 6p target back in March '19

it does annoy me though when the announcement starts with a very positive statement but when you look at the main numbers they are worse than the same period last year (generally)........I like the dividend increase as it suggests confidence BUT the new senior management roles mentioned seems to be adding costs

yes hopefully the results 23/1 will be positive.........I was invested here some time ago a couple of times and consistently lost money. It is nice to get some profit now.

Re car batteries I think it may generate some R&D fees in the short term BUT the actual prototype is still a long way off (but may generate some good IPR)

another day of large rises - volume seems normal - perhaps it is the CES hype helping but this has been going on for a while now

Still headed upwards on no news.........there seem to be daily buys around the £13K - £15K level but no other large trades I can see